NICE numbers at 20 Archives -

NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend

Nice numbers at 20: what end-of-life evidence does NICE draw on?

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/

NICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends

NICE numbers at 20: trends in deals

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/

There has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for

NICE numbers at 20 – a closer look at cancer

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/

Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0

NICE’s track record in cancer drugs: the impact of the CDF and interim funding

https://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/

Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed

NICE numbers at 20

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/

NICE numbers at 20